Potassium Citrate Anhydrous

Summary

Potassium Citrate Anhydrous (CHEMBL1200458) is an approved small-molecule diuretic.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Clinical trials: 23
• Chemistry: 306.39 Da · C6H5K3O7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200458
Name	Potassium Citrate Anhydrous
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	13344
ChEBI	CHEBI:64733
Molecular formula	C6H5K3O7
Molecular weight	306.39
InChIKey	QEEAPRPFLLJWCF-UHFFFAOYSA-K

SMILES: C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[K+].[K+].[K+]

IUPAC name: tripotassium;2-hydroxypropane-1,2,3-tricarboxylate

ChEBI definition: The anhydrous form of the tripotassium salt of citric acid.

Pharmacological roles (ChEBI): diuretic.

Also known as: Potassium citrate anhydrous, Potassium Citrate, Potassium citrate

Parent form; salt/anhydrous children: CHEMBL3989822

Patent coverage: 21,937 distinct patent families (58,788 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 23.

Phase distribution

Phase	Trials
Not specified	8
PHASE4	4
PHASE3	4
PHASE2/PHASE3	2
PHASE2	2
PHASE1/PHASE2	1
EARLY_PHASE1	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06003348	PHASE4	RECRUITING	Hydroxycitrate: A Novel Therapy for Calcium Phosphate Urinary Stones
NCT06966635	PHASE4	RECRUITING	Exploratory Study on the Treatment of Gout With Potassium Citrate Sustained-release Tablets
NCT00357331	PHASE4	COMPLETED	The Effects of Potassium Citrate on Bone Metabolism
NCT03342456	PHASE4	COMPLETED	The Efficacy and Safety of Ilaprazole/Doxycycline-based Bismuth-containing Quadruple Therapy on Hp Infected Duodenal Ulcers
NCT05918029	PHASE2/PHASE3	RECRUITING	Bone in CKD Alkali Response (BICARb Pilot Trial)
NCT06819553	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	A Randomized Clinical Trial to Evaluate the Effectiveness of Oral Potassium Citrate in Preventing Ureteral Stent Encrustation in Patients Undergoing Ureteroscopy for Uric Acid Kidney Stones
NCT00004284	PHASE3	COMPLETED	Phase III Randomized, Double-Blind Study of Potassium Phosphate Vs Potassium Citrate for Absorptive Hypercalciuria
NCT00509405	PHASE3	COMPLETED	Effect of Neutralization of Endogenous Acid Production on BMD and Bone Microarchitectural
NCT01756547	PHASE3	UNKNOWN	Study to Assess the Efficacy and Safety of Oral Potassium Citrate on the Prevention of Nephrocalcinosis in Extreme Premature
NCT03809884	PHASE3	COMPLETED	Dietary Counseling or Potassium Supplement to Increase Potassium Intake in Patients With High Blood Pressure
NCT07408076	PHASE1/PHASE2	NOT_YET_RECRUITING	Sodium Bicarbonate as an Alternative to Potassium Citrate for Kidney Stones
NCT00913796	PHASE2	COMPLETED	Metabolic Acidosis in Renal Transplant Patients
NCT01754779	PHASE2	COMPLETED	Treatment for Calcium Phosphate Kidney Stone Disease
NCT06335537	PHASE1	RECRUITING	Impact of Sodium Bicarbonate on 24-hour Urine Parameters in Hypocitriuric and Uric Acid Stone Formers
NCT04651088	EARLY_PHASE1	NOT_YET_RECRUITING	Comparing Alkalinizing Agents Efficacy on Stone Risk in Patients on a Metabolically Controlled Diet
NCT03253172	Not specified	ACTIVE_NOT_RECRUITING	Potassium Supplementation in CKD
NCT05389995	Not specified	ACTIVE_NOT_RECRUITING	Potassium Citrate and Crystal Light Lemonade
NCT07202832	Not specified	NOT_YET_RECRUITING	Urine Alkalinization for UTI in Women: RCT
NCT00120731	Not specified	WITHDRAWN	Effects of Potassium Citrate in Urine of Children With Elevated Calcium in Urine and Kidney Stones
NCT00282126	Not specified	COMPLETED	Potassium Citrate to Prevent Age Related Bone Loss
NCT02731820	Not specified	COMPLETED	Efficacy of Potassium Citrate in the Treatment of Postmenopausal Osteopenia
NCT03281928	Not specified	TERMINATED	Effect of Dietary Sodium and Potassium Citrate on Renal Mineral Handling
NCT03836144	Not specified	COMPLETED	Effect of Urine Alkalinazation on Urinary Inflammatory Markers in Patients With Cystinuria

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).